[Cellular immunotherapy for malignant glioma].
Okamoto
Yoshikazu
Y
Fujii Neurosurgical Hospital.
Yamashita
Junkoh
J
D000951:Antigens, Neoplasm / Q000276:immunology; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D015815:Cell Adhesion Molecules / Q000502:physiology; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation; D053222:Fas Ligand Protein; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D008562:Membrane Glycoproteins; D011948:Receptors, Antigen, T-Cell; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D016212:Transforming Growth Factor beta; D048069:Tumor Necrosis Factors
D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D011948:Receptors, Antigen, T-Cell; D016212:Transforming Growth Factor beta; D048069:Tumor Necrosis Factors; D007371:Interferon-gamma